Sjögren's syndrome, which is affected hundreds of millions of people worldwide, is a chronic autoimmune disorder characterized by leukocytic infiltration into the exocrine glands, such as the salivary and lacrimal glands. However, the pathological mechanism remains to be elucidated, and urgent need for the novel treatment should still meet. Over the past decades, an extensive progress has been made in establishment of Sjögren's syndrome model in mice, which offers us an invaluable tool to understand SjS pathogenesis and makes it possible to develop the novel drug and treatment. Here, we identified the potential effect of Tofacitinib, Filgotinib and Ruxolitinib on the experimental Sjögren's syndrome model in C57/B6L mice from both In-life study and ex-vivo study at the endpoint. Our data suggest that Tofacitinib, Filgotinib and Ruxolitinib, three JAK inhibtors exhibits the effect on reducing the severity of Sjögren's syndrome in mice, reduces autoantibodies producion and promotes the saliva secretion in mice, which also provides the direction of novel JAK inhibitor on treatment for Sjögren's syndrome.

Citation Format: Ruiqing Yan, Yanping Yuan, Chao Luo, Chuanzhi Yangmeng, Li Fang, Qing Lin. Identification of Tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren's syndrome model in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1036.